Drafting program · Review edition
Review the completed work
AI-assisted draft, not yet reviewed
21 of 33 medicine packets are complete as drafts. Each includes expanded audience explanations, targeted or full FAQ sets, source-linked evidence and editorial checks. The remaining 12 medicines are still in the drafting queue.
These pages are public review drafts. They are not a record of clinical approval, adopted policies or verified translation. Existing visual guides remain available.
Medicine drafts
- Ozempic10 perspectives · evidence & review notes
- Wegovy10 perspectives · evidence & review notes
- Mounjaro10 perspectives · evidence & review notes
- Zepbound10 perspectives · evidence & review notes
- Metformin10 perspectives · evidence & review notes
- Atorvastatin10 perspectives · evidence & review notes
- Lisinopril10 perspectives · evidence & review notes
- Amlodipine10 perspectives · evidence & review notes
- Sertraline10 perspectives · evidence & review notes
- Omeprazole10 perspectives · evidence & review notes
- Ibuprofen10 perspectives · evidence & review notes
- Levothyroxine10 perspectives · evidence & review notes
- Losartan10 perspectives · evidence & review notes
- Metoprolol10 perspectives · evidence & review notes
- Rosuvastatin10 perspectives · evidence & review notes
- Albuterol10 perspectives · evidence & review notes
- Apixaban10 perspectives · evidence & review notes
- Empagliflozin10 perspectives · evidence & review notes
- Rybelsus10 perspectives · evidence & review notes
- Trulicity10 perspectives · evidence & review notes
- Foundayo10 perspectives · evidence & review notes
Trust and policy drafts
Unresolved founder fields are marked. These texts are proposals for review, not statements that every described process is already operating.
- About
- Team
- Editorial Policy
- Medical Review
- Sources
- Ai Use
- Corrections
- Privacy
- Terms
- Contact
- Funding
- Accessibility
Still being prepared
Esketamine, sodium oxybate, modafinil, glipizide, ezetimibe, famotidine, ondansetron, adalimumab, Victoza, Saxenda, Byetta and Bydureon BCise. Site-wide improvements, translation QA and feedback specifications are also in progress.